Treatments delivered

We’ve developed 12 treatments for six deadly diseases since 2003

Treatments delivered

We’ve developed 12 treatments for six deadly diseases since 2003

Delivering better treatments for neglected patients

DNDi’s objective is to deliver 25 new treatments for neglected patients by 2028.

Since 2003, DNDi has worked with its worldwide network of partners to:

  • develop two new chemical entities: fexinidazole, the first all-oral treatment for sleeping sickness, and ravidasvir, a simple-to-use and affordable treatment for hepatitis C
  • develop 10 new treatments from existing molecules and recombining drugs to bring better treatments to patients for malaria, Chagas disease, leishmaniasis, HIV-visceral leishmaniasis co-infection, and paediatric HIV
  • initiate GARDP, a not-for-profit research and development organization developing and delivering new or improved antibiotic treatments

Treatments delivered

Mother holding her baby in a hospital

New recommendations for treating visceral leishmaniasis in Latin America

Liposomal amphotericin B recommended instead of pentavalent antimonials

Partnership with the University of Brasilia and the Oswaldo Cruz Foundation of Brazil.

Caregiver prepares 4-in-1 HIV treatment for child

‘4-in-1’ antiretroviral treatment

Child-friendly treatment specifically designed for infants and young children with HIV

Partnership with Cipla Limited

Doctor with a patient

New treatments for HIV/VL

Better treatment for people co-infected with HIV and visceral leishmaniasis

Partnership with Médecins Sans Frontières and other partners.

Former HCV patient looking at his mother


An affordable hepatitis C cure to leave no one behind

Partnership with Ministries of Health of Malaysia and Thailand, Pharmaniaga, Pharco Pharmaceuticals, and Médecins Sans Frontières France.

Fexinidazole pill in a hand


First all-oral cure for all stages of sleeping sickness

Partnership with Sanofi, the Human African Trypanosomiasis Platform, Médecins Sans Frontières, national control programmes, and WHO.

GARDP logo


Incubation of the Global Antibiotic Research & Development Partnership (GARDP) to address antimicrobial resistance

Partnership with WHO

Mother kissing her child

Super-booster therapy

More effective treatment for children with HIV and TB

Partnership with the Department of Health, South Africa

New visceral leishmaniasis treatments in Asia

New visceral leishmaniasis treatments in Asia

Better treatments in South Asia

Partnerships with kala-azar actors in South Asia including ministries of health, research institutes, NGOs, and WHO-TDR.

Box of Abarax 12.5mg

Paediatric Benznidazole

First paediatric drug for Chagas disease

Partnership with LAFEPE (Brazil) to develop the first paediatric treatment for Chagas (2011); subsequent partnerships with Chemo Research, Exeltis USA, Mundo Sano Foundation, and Laboratorio ELEA PHOENIX.

SSG&PM treatment


Cheaper, more effective visceral leishmaniasis treatment in Africa

Partnership with the Leishmaniasis East Africa Platform (LEAP), national control programmes, Médecins Sans Frontières, and WHO.

NECT treatment

Nifurtimox-eflornithine combination therapy (NECT)

Better, safer treatment for sleeping sickness

Partnership with Médecins Sans Frontières, Epicentre, national control programmes, and WHO.

ASMQ treatment


Fixed-dose combination of artesunate and mefloquine for malaria

Partnership with Farmanguinhos/Fiocruz (Brazil) and Cipla (India)

*Project handed over to Medicines for Malaria Venture in 2015

ASAQ treatment


Fixed-dose combination of artesunate and amodiaquine to treat malaria

Partnership with Sanofi

*Project handed over to Medicines for Malaria Venture in 2015